tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

MDTMedtronic

Health care · Medical Devices · NYSE
MDT quote by TradingView
Compare with peers → Embed
FY2026 at a glance

Sales up 8.4%, free cash flow up to $5.4B

XBRL, from each 10-K
RevenueStatements ↓
$36.4B
from $33.5B in FY2025
FY2017FY2026
Net incomeStatements ↓
$4.8B
from $4.7B in FY2025
FY2017FY2026
Free cash flowStatements ↓
$5.4B
from $5.2B in FY2025
FY2017FY2026
EPS (diluted)Statements ↓
$3.73
from $3.61 in FY2025
FY2017FY2026
Operating marginStatements ↓
17.8%
from 17.8% in FY2025
FY2017FY2026
Total debtStatements ↓
$28.0B
from $25.6B in FY2025
FY2017FY2026
Price and key numbers

The latest figures

All key numbers (40, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)4.06Sales (ttm)37.5BNet income (ttm)5.2BSales growth+8.4%EPS growth+3.3%Sales Q/Q+13.7%
Free cash flow6.1BGross margin65.0%Oper. margin18.1%Net margin13.9%FCF margin16.3%ROE10.4%
ROA5.6%R&D / sales7.9%Dividend2.84Debt/Eq0.56Curr. ratio2.07Cash1.7B
Op. cash flow (ttm)8.0BEBITDA9.4BEBITDA margin25.9%Net debt26.5BQuick ratio1.56Interest cover9.04
ROIC6.5%Payout ratio76.1%Tax rate21.2%Stock pay / sales1.3%Shares out.1.3BShares Y/Y-0.1%
Book / share39.27Cash / share1.32Sales / share29.35Asset turnover0.40Inventory turns2.14Days sales out.67
Sales 3Y CAGR+5.2%Sales 5Y CAGR+3.9%EPS 3Y CAGR+9.8%EPS 5Y CAGR+7.0%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

MDT against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
MDTPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
+8.4%26th of 60 · median +7.1%
Net margin
13.9%23rd of 60 · median 9.6%
Return on equity
10.4%33rd of 54 · median 13.1%
Free cash flow margin
16.3%25th of 56 · median 15.5%
Debt / equity (less is better)
0.5618th of 49 · median 0.66
MDT and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
MDT Medtronic$37.5B +8.4%65.0%13.9%10.4%16.3%0.56
ABT Abbott Laboratories$48.2B +5.7%56.9%9.7%9.2%14.0%0.61
TMO Thermo Fisher Scientific$47.4B +3.9%-14.9%12.9%16.0%0.79
AMGN Amgen$38.9B +10.0%70.9%24.1%65.4%24.6%3.76
GILD Gilead Sciences$31.0B +2.4%79.9%-12.5%-29.6%44.5%2.01
SYK Stryker Corporation$26.3B +11.2%65.3%13.8%15.4%17.4%0.61
Where each dollar goes

From $31.7B of sales to $5.0B of profit

FY2022, from the 10-K income statement
Revenue to Gross profit: $21.5BRevenue to Cost of revenue: $10.1BGross profit to Operating profit: $5.8BGross profit to Operating expenses: $15.8BOperating profit to Net profit: $5.0BOperating profit to Tax & other: $713.0MOperating expenses to R&D: $2.7BOperating expenses to Sales, admin & other: $13.0B Revenue: $31.7B Revenue$31.7B +5% Y/Y Gross profit: $21.5B · 68% margin Gross profit$21.5B68% margin Cost of revenue: $10.1B · 32% of revenue Cost of revenue$10.1B32% of revenue Operating profit: $5.8B · 18% margin Operating profit$5.8B18% margin +28% Y/Y Operating expenses: $15.8B · 50% of revenue Operating expenses$15.8B50% of revenue Net profit: $5.0B · 16% margin Net profit$5.0B16% margin +40% Y/Y Tax & other: $713.0M · 2% of revenue Tax & other$713.0M2% of revenue R&D: $2.7B · 9% of revenue R&D$2.7B9% of revenue Sales, admin & other: $13.0B · 41% of revenue Sales, admin & other$13.0B41% of revenue

Swipe sideways for the whole flow →

From $31.2B of sales to $3.8B of profit

FY2023, from the 10-K income statement
Revenue to Gross profit: $20.5BRevenue to Cost of revenue: $10.7BGross profit to Operating profit: $5.5BGross profit to Operating expenses: $15.0BOperating profit to Net profit: $3.8BOperating profit to Tax & other: $1.7BOperating expenses to R&D: $2.7BOperating expenses to Sales, admin & other: $12.3B Revenue: $31.2B Revenue$31.2B −1% Y/Y Gross profit: $20.5B · 66% margin Gross profit$20.5B66% margin Cost of revenue: $10.7B · 34% of revenue Cost of revenue$10.7B34% of revenue Operating profit: $5.5B · 18% margin Operating profit$5.5B18% margin −5% Y/Y Operating expenses: $15.0B · 48% of revenue Operating expenses$15.0B48% of revenue Net profit: $3.8B · 12% margin Net profit$3.8B12% margin −25% Y/Y Tax & other: $1.7B · 6% of revenue Tax & other$1.7B6% of revenue R&D: $2.7B · 9% of revenue R&D$2.7B9% of revenue Sales, admin & other: $12.3B · 39% of revenue Sales, admin & other$12.3B39% of revenue

Swipe sideways for the whole flow →

From $32.4B of sales to $3.7B of profit

FY2024, from the 10-K income statement and revenue by segment
Neuroscience Group to Revenue: $9.4BMedical Surgical to Revenue: $8.4BDiabetes Group to Revenue: $2.5BOther Operating Segment Misc to Revenue: $221.0MNeuroscience to Revenue: $9.4BOther to Revenue: $2.9BRevenue to Gross profit: $21.1BRevenue to Cost of revenue: $11.2BGross profit to Operating profit: $5.1BGross profit to Operating expenses: $16.0BOperating profit to Net profit: $3.7BOperating profit to Tax & other: $1.5BOperating expenses to R&D: $2.7BOperating expenses to Sales, admin & other: $13.3B Neuroscience Group: $9.4B · 29% Neuroscience Group$9.4B29% Medical Surgical: $8.4B · 26% Medical Surgical$8.4B26% Diabetes Group: $2.5B · 8% Diabetes Group$2.5B8% Other Operating Segment Misc: $221.0M · 1% Other Operating Segment…$221.0M1% Neuroscience: $9.4B · 29% Neuroscience$9.4B29% Other: $2.9B · 9% Other$2.9B9% Revenue: $32.4B Revenue$32.4B +4% Y/Y Gross profit: $21.1B · 65% margin Gross profit$21.1B65% margin Cost of revenue: $11.2B · 35% of revenue Cost of revenue$11.2B35% of revenue Operating profit: $5.1B · 16% margin Operating profit$5.1B16% margin −6% Y/Y Operating expenses: $16.0B · 49% of revenue Operating expenses$16.0B49% of revenue Net profit: $3.7B · 11% margin Net profit$3.7B11% margin −2% Y/Y Tax & other: $1.5B · 5% of revenue Tax & other$1.5B5% of revenue R&D: $2.7B · 8% of revenue R&D$2.7B8% of revenue Sales, admin & other: $13.3B · 41% of revenue Sales, admin & other$13.3B41% of revenue

Swipe sideways for the whole flow →

From $33.5B of sales to $4.7B of profit

FY2025, from the 10-K income statement
Revenue to Gross profit: $21.9BRevenue to Cost of revenue: $11.6BGross profit to Operating profit: $6.0BGross profit to Operating expenses: $15.9BOperating profit to Net profit: $4.7BOperating profit to Tax & other: $1.3BOperating expenses to R&D: $2.7BOperating expenses to Sales, admin & other: $13.2B Revenue: $33.5B Revenue$33.5B +4% Y/Y Gross profit: $21.9B · 65% margin Gross profit$21.9B65% margin Cost of revenue: $11.6B · 35% of revenue Cost of revenue$11.6B35% of revenue Operating profit: $6.0B · 18% margin Operating profit$6.0B18% margin +16% Y/Y Operating expenses: $15.9B · 48% of revenue Operating expenses$15.9B48% of revenue Net profit: $4.7B · 14% margin Net profit$4.7B14% margin +27% Y/Y Tax & other: $1.3B · 4% of revenue Tax & other$1.3B4% of revenue R&D: $2.7B · 8% of revenue R&D$2.7B8% of revenue Sales, admin & other: $13.2B · 39% of revenue Sales, admin & other$13.2B39% of revenue

Swipe sideways for the whole flow →

From $36.4B of sales to $4.8B of profit

FY2026, from the 10-K income statement and revenue by segment
Cardiovascular to Revenue: $14.0BNeuroscience Group to Revenue: $10.3BMedical Surgical to Revenue: $8.8BDiabetes Group to Revenue: $3.1BOther Operating Segment Misc to Revenue: $135.0MRevenue to Gross profit: $23.6BRevenue to Cost of revenue: $12.7BGross profit to Operating profit: $6.5BGross profit to Operating expenses: $17.2BOperating profit to Net profit: $4.8BOperating profit to Tax & other: $1.7BOperating expenses to R&D: $2.9BOperating expenses to Sales, admin & other: $14.3B Cardiovascular: $14.0B · 38% Cardiovascular$14.0B38% Neuroscience Group: $10.3B · 28% Neuroscience Group$10.3B28% Medical Surgical: $8.8B · 24% Medical Surgical$8.8B24% Diabetes Group: $3.1B · 9% Diabetes Group$3.1B9% Other Operating Segment Misc: $135.0M · 0% Other Operating Segment…$135.0M0% Revenue: $36.4B Revenue$36.4B +8% Y/Y Gross profit: $23.6B · 65% margin Gross profit$23.6B65% margin Cost of revenue: $12.7B · 35% of revenue Cost of revenue$12.7B35% of revenue Operating profit: $6.5B · 18% margin Operating profit$6.5B18% margin +9% Y/Y Operating expenses: $17.2B · 47% of revenue Operating expenses$17.2B47% of revenue Net profit: $4.8B · 13% margin Net profit$4.8B13% margin +3% Y/Y Tax & other: $1.7B · 5% of revenue Tax & other$1.7B5% of revenue R&D: $2.9B · 8% of revenue R&D$2.9B8% of revenue Sales, admin & other: $14.3B · 39% of revenue Sales, admin & other$14.3B39% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2022
FY2023
FY2024
FY2025
FY2026
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

2 of 3
  • ✓
    Net margin above the peer median13.9% vs 9.6%
  • !
    Return on equity below 15%10.4%
  • ✓
    A profit in every one of 10 years
Net margin, FY2017 to FY2026: 13.6% → 13.2%

Balance sheet

3 of 4
  • ✓
    Interest covered more than 5 timesOperating income is 9.0× interest expense
  • ✓
    Debt smaller than equityDebt / equity 0.56 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 2.07
  • !
    Net debt over 3 years of free cash flow$19.2B net debt, 3.1 years
Debt / equity at each year end, FY2017 to FY2026: 0.67 → 0.57
What the debt is made of ↓

Cash and shareholders

4 of 4
  • ✓
    Free cash flow positive in every one of 10 years$5.4B last year
  • ✓
    Share count down over 5 years−4.9%
  • ✓
    Dividend per share up over 5 years$2.32 → $2.84
  • ✓
    Cash from operations above net income$7.3B vs $4.8B
Free cash flow, FY2017 to FY2026: 5.6B → 5.4B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Debt

$28.1B of principal due, schedule of Apr 24, 2026

Repayment schedule →

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Revenue and net income, FY2017 to FY2026

Revenue 36.4B Net income 4.8B
FY2017 revenue 29.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001613103-19-000028 FY2017 net income 4.0B · NetIncomeLoss, 0001613103-19-000028 29.7B FY2017 FY2018 revenue 30.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001613103-20-000021 FY2018 net income 3.1B · NetIncomeLoss, 0001613103-20-000021 30.0B FY2018 FY2019 revenue 30.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001613103-21-000027 FY2019 net income 4.6B · NetIncomeLoss, 0001613103-21-000027 30.6B FY2019 FY2020 revenue 28.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001613103-22-000023 FY2020 net income 4.8B · NetIncomeLoss, 0001613103-22-000023 28.9B FY2020 FY2021 revenue 30.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001613103-23-000040 FY2021 net income 3.6B · NetIncomeLoss, 0001613103-23-000040 30.1B FY2021 FY2022 revenue 31.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001613103-24-000072 FY2022 net income 5.0B · NetIncomeLoss, 0001613103-24-000072 31.7B FY2022 FY2023 revenue 31.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001613103-25-000091 FY2023 net income 3.8B · NetIncomeLoss, 0001613103-25-000091 31.2B FY2023 FY2024 revenue 32.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-044354 FY2024 net income 3.7B · NetIncomeLoss, 0001628280-26-044354 32.4B FY2024 FY2025 revenue 33.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-044354 FY2025 net income 4.7B · NetIncomeLoss, 0001628280-26-044354 33.5B FY2025 FY2026 revenue 36.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-044354 FY2026 net income 4.8B · NetIncomeLoss, 0001628280-26-044354 36.4B FY2026

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

Statements

Income statement, balance sheet and cash flow

XBRL, each 10-K and 10-Q

MDT's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue36.4B
FY2017: 29.7BFY2018: 30.0BFY2019: 30.6BFY2020: 28.9BFY2021: 30.1BFY2022: 31.7BFY2023: 31.2BFY2024: 32.4BFY2025: 33.5BFY2026: 36.4B FY2018FY2020FY2022FY2024FY2026
Net income4.8B
FY2017: 4.0BFY2018: 3.1BFY2019: 4.6BFY2020: 4.8BFY2021: 3.6BFY2022: 5.0BFY2023: 3.8BFY2024: 3.7BFY2025: 4.7BFY2026: 4.8B FY2018FY2020FY2022FY2024FY2026
Free cash flow5.4B
FY2017: 5.6BFY2018: 3.6BFY2019: 5.9BFY2020: 6.0BFY2021: 4.9BFY2022: 6.0BFY2023: 4.6BFY2024: 5.2BFY2025: 5.2BFY2026: 5.4B FY2018FY2020FY2022FY2024FY2026
EPS (diluted)3.73
FY2017: 2.89FY2018: 2.27FY2019: 3.41FY2020: 3.54FY2021: 2.66FY2022: 3.73FY2023: 2.82FY2024: 2.76FY2025: 3.61FY2026: 3.73 FY2018FY2020FY2022FY2024FY2026
Dividend per share2.84
FY2017: 1.72FY2018: 1.84FY2019: 2.00FY2020: 2.16FY2021: 2.32FY2022: 2.52FY2023: 2.72FY2024: 2.76FY2025: 2.80FY2026: 2.84 FY2018FY2020FY2022FY2024FY2026
Diluted shares1.3B
FY2017: 1.4BFY2018: 1.4BFY2019: 1.4BFY2020: 1.4BFY2021: 1.4BFY2022: 1.4BFY2023: 1.3BFY2024: 1.3BFY2025: 1.3BFY2026: 1.3B FY2018FY2020FY2022FY2024FY2026

The segments changed

10-K filed 2026-06-18

Compared with the 10-K of Jun 20, 2025: new segments Diabetes Group, Neuroscience Group, Other Operating Segment Misc, Other Operating Segments Including Diabetes; no longer reported: Diabetes, Neuroscience, Other, All Other Segments.

When a company changes its segments, the years before are usually recast, so growth by segment is not comparable with what earlier 10-Ks showed. Found by comparing the segments with revenue in the last two 10-Ks (XBRL) and by the 10-K's own words, without AI.

Revenue by business segment

year to Apr 24, 2026
RevenueSharevs year before
Cardiovascular 14.0B38.4% +12.0%
Neuroscience Group 10.3B28.3% +4.5%
Medical Surgical 8.8B24.2% +4.9%
Other Operating Segments Including Diabetes 3.2B8.9% +12.3%
Diabetes Group 3.1B8.6% +13.0%
Other Operating Segment Misc 135.0M0.4% -1.5%

10-K 0001628280-26-044354, segment and revenue notes (XBRL).

Revenue by region

year to Apr 24, 2026
RevenueSharevs year before
Non-US 18.3B50.2% +11.6%
U.S. 18.1B49.8% +5.4%
Ireland 143.0M0.4% +23.3%

10-K 0001628280-26-044354, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue29.7B30.0B30.6B28.9B30.1B31.7B31.2B32.4B33.5B36.4B
Cost of revenue9.3B9.1B9.2B9.4B10.5B10.1B10.7B11.2B11.6B12.7B
Gross profit20.4B20.9B--------
R&D2.2B2.3B2.3B2.3B2.5B2.7B2.7B2.7B2.7B2.9B
SG&A10.0B10.2B10.4B10.1B10.1B10.3B10.4B10.7B10.8B11.8B
Operating income5.4B6.6B6.3B4.8B4.5B5.8B5.5B5.1B6.0B6.5B
Interest expense1.1B1.1B1.4B1.1B925.0M553.0M636.0M719.0M729.0M715.0M
Pretax income4.6B5.7B5.2B4.1B3.9B5.5B5.4B4.8B5.6B6.1B
Income tax578.0M2.6B547.0M-751.0M265.0M456.0M1.6B1.1B936.0M1.3B
Net income4.0B3.1B4.6B4.8B3.6B5.0B3.8B3.7B4.7B4.8B
EPS (diluted)2.892.273.413.542.663.732.822.763.613.73
Diluted shares1.4B1.4B1.4B1.4B1.4B1.4B1.3B1.3B1.3B1.3B
Depreciation & amortization2.9B2.6B2.7B2.7B2.7B2.7B2.7B2.6B2.9B3.0B
EBITDA8.3B9.3B8.9B7.5B7.2B8.5B8.2B7.8B8.8B9.4B
Gross margin68.7%69.8%--------
Operating margin18.1%22.2%20.5%16.6%14.9%18.2%17.6%15.9%17.8%17.8%
Net margin13.6%10.4%15.2%16.6%12.0%15.9%12.0%11.4%13.9%13.2%
Revenue growth-+0.8%+2.0%-5.4%+4.2%+5.2%-1.4%+3.6%+3.6%+8.4%
EPS growth--21.5%+50.2%+3.8%-24.9%+40.2%-24.4%-2.1%+30.8%+3.3%

Balance sheet

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash5.0B3.7B4.4B4.1B3.6B3.7B1.5B1.3B2.2B1.9B
Short-term investments8.7B7.6B5.5B6.8B7.2B6.9B6.4B6.7B6.7B7.3B
Receivables5.6B6.0B6.2B4.6B5.5B5.6B6.0B6.1B6.5B6.6B
Inventory3.3B3.6B3.8B4.2B4.3B4.6B5.3B5.2B5.5B6.0B
Current assets24.9B23.0B22.0B22.0B22.5B23.1B21.7B21.9B23.8B24.8B
Property & equipment4.4B4.6B4.7B4.8B5.2B5.4B5.6B6.1B6.8B7.4B
Goodwill38.5B39.5B40.0B39.8B42.0B40.5B41.4B41.0B41.7B42.6B
Total assets99.9B91.4B89.7B90.7B93.1B91.0B90.9B90.0B91.7B93.0B
Accounts payable1.6B1.6B2.0B2.0B2.1B2.3B2.7B2.4B2.4B2.6B
Current liabilities14.3B10.1B8.5B10.4B8.5B12.4B9.1B10.8B12.9B11.7B
Total debt33.4B25.8B25.3B24.8B26.4B24.1B24.3B25.0B25.6B28.0B
Total liabilities49.5B40.6B39.5B39.8B41.5B38.3B39.3B39.6B43.4B43.0B
Shareholders' equity50.2B50.7B50.1B50.7B51.4B52.6B51.5B50.2B48.0B49.5B
Retained earnings23.3B24.4B26.3B28.1B28.6B30.2B30.4B30.4B31.5B32.6B

Cash flow

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow6.9B4.7B7.0B7.2B6.2B7.3B6.0B6.8B7.0B7.3B
Capital spending1.3B1.1B1.1B1.2B1.4B1.4B1.5B1.6B1.9B1.9B
Free cash flow5.6B3.6B5.9B6.0B4.9B6.0B4.6B5.2B5.2B5.4B
Stock-based pay (added back)348.0M344.0M290.0M297.0M344.0M359.0M355.0M393.0M429.0M457.0M
Dividends paid2.4B2.5B2.7B2.9B3.1B3.4B3.6B3.7B3.6B3.6B
Buybacks3.5B2.2B2.9B1.3B652.0M2.5B645.0M2.1B3.2B1.0B
Acquisitions1.3B137.0M1.8B488.0M994.0M91.0M1.9B211.0M98.0M406.0M
Debt raised2.1B21.0M7.8B5.6B7.2B05.4B03.2B1.7B
Debt repaid863.0M7.4B7.9B6.1B7.4B1.0M6.0B002.9B
Investing cash flow-1.6B5.9B-774.0M-3.2B-2.9B-1.7B-3.5B-2.4B-1.9B-2.9B
Financing cash flow-3.3B-12.0B-5.4B-4.2B-4.1B-5.3B-5.0B-4.5B-4.4B-4.8B
Dividend per share1.721.842.002.162.322.522.722.762.802.84

Stock-based pay and leases

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Stock-based pay (expense)348.0M344.0M290.0M297.0M344.0M359.0M355.0M393.0M429.0M457.0M
Stock-based pay / revenue1.2%1.1%0.9%1.0%1.1%1.1%1.1%1.2%1.3%1.3%
Operating lease cost---223.0M216.0M195.0M211.0M232.0M232.0M251.0M
Operating lease cash paid---221.0M216.0M174.0M210.0M232.0M233.0M270.0M
Right-of-use assets--1.0B927.0M998.0M854.0M1.0B1.0B1.1B1.2B
Operating lease liabilities--1.0B945.0M1.0B871.0M1.0B1.0B1.1B1.2B

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Next Peers in numbers →